Cardiocel revenue should kick in gradually and then accelerate as its fame expands globally during
A big cost will be funding of the phase 2a hsv2 and the hpv phase 1 trials. Not sure how much they will cost but with say $7 mil in the kitty they can probably at least fund the hsv2 trial which if successful would attract no end of partnership opportunities with consequent funding progressing those vaccine trials further.
Cardiocel revenue may then be sufficient on its own to launch the hpv trial.
Just a hypothesis but i agree at this point of time a cr is not needed.
Fox
line wipe, page-41
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.20 |
Change
-0.550(3.10%) |
Mkt cap ! $330.6M | |||
| Open | High | Low | Value | Volume |
| $17.75 | $17.75 | $16.88 | $199.1K | 11.56K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 500 | $17.00 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.24 | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |